Wed, Nov 26, 2014, 11:46 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Alexza Pharmaceuticals Inc. Message Board

  • darthnvader darthnvader May 14, 2013 4:08 PM Flag

    1st quarter loss $1.31 a share

    I never like to hold into earnings, this could pounce the stock. I am on the side lines.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • stock is moving up lol

    • more than half of that was a non-cash charge...there's nothing to pounce anyway - what - .10? Probably end up doing nothing or going up a little now that the quarter is out of the way

    • when investing in start up bio's its all about looking forward......period.....

    • Past earnings are a non-event because the stock market is a forward-looking discounting mechanism.

      Earnings highlights:
      *In February 2013, the European Commission granted marketing authorization for ADASUVE (Staccato loxapine), 4.5 mg and 9.1 mg inhalation powder, pre-dispensed, for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
      *In March 2013, Alexza commenced the commercial manufacturing of ADASUVE in its facility in Mountain View, CA. Product manufactured at this facility is intended to supply the U.S. and EU markets.
      *In May 2013, Alexza entered into an exclusive U.S. license and supply agreement for ADASUVE with Teva Pharmaceuticals USA, Inc. Teva will be responsible for all U.S. development and commercialization activities for ADASUVE, including U.S. post-approval clinical studies. Alexza will be responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.
      *Alexza received an upfront cash payment of $40 million, $10 million of which will be paid to the former stockholders of Symphony Allegro, Inc. Alexza is eligible to receive up to $195 million in additional milestone payments contingent on successful completion of the ADASUVE post-approval studies in the U.S. and achievement of specified net sales targets. For product shipped to Teva, Alexza will receive a specified per-unit transfer price based on costs of commercial production, which transfer price will convert to a fixed price upon achievement of costs equal to a specified per-unit price. Teva will make tiered royalty payments based on net commercial sales of ADASUVE in the U.S.

1.44-0.02(-1.37%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SeaDrill Limited
NYSEWed, Nov 26, 2014 4:01 PM EST
KLA-Tencor Corporation
NasdaqGSWed, Nov 26, 2014 4:00 PM EST
TASER International Inc.
NasdaqGSWed, Nov 26, 2014 4:00 PM EST